Demis Hassabis, CEO of Google DeepMind, has stated that the company had to return to its startup roots after the Brain merger in 2023. He described the transformation as a cultural adjustment as much as a structural one. Hassabis also revealed that he runs Isomorphic Labs, the group’s pharmaceutical AI spinoff, as a “second workday” beginning around 10pm ahead of expected human trials in oncology later this year. He said that 90% of the breakthroughs underpinning the modern AI industry were produced by either Google Brain, Google Research, or DeepMind. The company's focus on AI-driven drug discovery has led to a product release cadence that has accelerated sharply.